Literature DB >> 34720818

Expert Discussion: Predictive Markers.

Angelo Paradiso1, Giovanni Codacci-Pisanelli2, Elisabetta Munzone3, Hope S Rugo4, Pierre Etienne Heudel5.   

Abstract

Entities:  

Year:  2021        PMID： 34720818      PMCID： PMC8543338          DOI： 10.1159/000519562

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.268


× No keyword cloud information.
  12 in total

1.  Should next-generation sequencing tests be performed on all cancer patients?

Authors:  Andrew J McKenzie; Holli H Dilks; Suzanne F Jones; Howard Burris
Journal:  Expert Rev Mol Diagn       Date:  2019-01-09       Impact factor: 5.225

2.  Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening.

Authors:  S Paluch-Shimon; F Cardoso; C Sessa; J Balmana; M J Cardoso; F Gilbert; E Senkus
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

3.  Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.

Authors:  P Schmid; R Salgado; Y H Park; E Muñoz-Couselo; S B Kim; J Sohn; S-A Im; T Foukakis; S Kuemmel; R Dent; L Yin; A Wang; K Tryfonidis; V Karantza; J Cortés; S Loi
Journal:  Ann Oncol       Date:  2020-02-14       Impact factor: 32.976

4.  Prospective Decision Analysis Study of Clinical Genomic Testing in Metastatic Breast Cancer: Impact on Outcomes and Patient Perceptions.

Authors:  Daniel G Stover; Raquel E Reinbolt; Elizabeth J Adams; Sarah Asad; Katlyn Tolliver; Mahmoud Abdel-Rasoul; Cynthia D Timmers; Susan Gillespie; James L Chen; Siraj Mahamed Ali; Katharine A Collier; Mathew A Cherian; Anne M Noonan; Sagar Sardesai; Jeffrey VanDeusen; Robert Wesolowski; Nicole Williams; Clara N Lee; Charles L Shapiro; Erin R Macrae; Bhuvaneswari Ramaswamy; Maryam B Lustberg
Journal:  JCO Precis Oncol       Date:  2019-11-18

5.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

6.  Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.

Authors:  S Dent; J Cortés; Y-H Im; V Diéras; N Harbeck; I E Krop; T R Wilson; N Cui; F Schimmoller; J Y Hsu; J He; M De Laurentiis; S Sousa; P Drullinsky; W Jacot
Journal:  Ann Oncol       Date:  2020-11-10       Impact factor: 32.976

Review 7.  ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.

Authors:  Jamie O Brett; Laura M Spring; Aditya Bardia; Seth A Wander
Journal:  Breast Cancer Res       Date:  2021-08-15       Impact factor: 6.466

8.  Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.

Authors:  H S Rugo; F André; T Yamashita; H Cerda; I Toledano; S M Stemmer; J C Jurado; D Juric; I Mayer; E M Ciruelos; H Iwata; P Conte; M Campone; C Wilke; D Mills; A Lteif; M Miller; F Gaudenzi; S Loibl
Journal:  Ann Oncol       Date:  2020-05-13       Impact factor: 32.976

9.  Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.

Authors:  F André; E M Ciruelos; D Juric; S Loibl; M Campone; I A Mayer; G Rubovszky; T Yamashita; B Kaufman; Y-S Lu; K Inoue; Z Pápai; M Takahashi; F Ghaznawi; D Mills; M Kaper; M Miller; P F Conte; H Iwata; H S Rugo
Journal:  Ann Oncol       Date:  2020-11-25       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.